468 related articles for article (PubMed ID: 29173004)
1. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
2. Definitions and statistical properties of master protocols for personalized medicine in oncology.
Renfro LA; Mandrekar SJ
J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
[TBL] [Abstract][Full Text] [Related]
3. Statistical issues and advances in cancer precision medicine research.
Nasution MD; Wang X
J Biopharm Stat; 2018; 28(2):215-216. PubMed ID: 29513634
[No Abstract] [Full Text] [Related]
4. Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps.
Printz C
Cancer; 2020 Jan; 126(2):239-240. PubMed ID: 31917472
[No Abstract] [Full Text] [Related]
5. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
6. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
Wang X; Zhou J; Wang T; George SL
J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
[TBL] [Abstract][Full Text] [Related]
7. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Collins DC; Sundar R; Lim JSJ; Yap TA
Trends Pharmacol Sci; 2017 Jan; 38(1):25-40. PubMed ID: 27871777
[TBL] [Abstract][Full Text] [Related]
8. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Lin JA; He P
Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
[TBL] [Abstract][Full Text] [Related]
9. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
Umelo IA; Costanza B; Castronovo V
Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
[TBL] [Abstract][Full Text] [Related]
10. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
11. Patient-specific multi-omics models and the application in personalized combination therapy.
John A; Qin B; Kalari KR; Wang L; Yu J
Future Oncol; 2020 Aug; 16(23):1737-1750. PubMed ID: 32462937
[TBL] [Abstract][Full Text] [Related]
12. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
13. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
14. Designing precision medicine trials to yield a greater population impact.
Zhao YQ; LeBlanc ML
Biometrics; 2020 Jun; 76(2):643-653. PubMed ID: 31598964
[TBL] [Abstract][Full Text] [Related]
15. Biomarker threshold adaptive designs for survival endpoints.
Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
[TBL] [Abstract][Full Text] [Related]
16. Innovative Designs, Methods and Application for Disease Risk Prediction and Drug Development: Frequentist, Bayesian, and Beyond.
Contemp Clin Trials; 2017 Dec; 63():1. PubMed ID: 29153293
[No Abstract] [Full Text] [Related]
17. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
18. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial designs for testing biomarker-based personalized therapies.
Lai TL; Lavori PW; Shih MC; Sikic BI
Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
[TBL] [Abstract][Full Text] [Related]
20. Precision oncology: A new era of cancer clinical trials.
Renfro LA; An MW; Mandrekar SJ
Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]